1. Monoamine oxidases (MAO-A and MAO-B) are enzymes that catalyze the oxidative deamination of neurotransmitters, leading to neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
2. MAO inhibition has a general anti-Alzheimer’s effect due to its role in reducing oxidative stress caused by MAO enzymes.
3. This review outlines recent understanding on MAO enzymes, their structure, physiological function, catalytic mechanism, and possible therapeutic goals in AD, as well as highlighting current developments and discoveries of potential MAO inhibitors from various chemical scaffolds.
The article is overall reliable and trustworthy. It provides an overview of the role of monoamine oxidase (MAO) enzymes in Alzheimer's disease (AD), including their structure, physiological function, catalytic mechanism, and possible therapeutic goals in AD. The article also highlights the current development and discovery of potential MAO inhibitors from various chemical scaffolds. The article is well-researched and provides evidence for its claims with references to relevant studies. It does not appear to be biased or one-sided in its reporting; rather it presents both sides equally by providing an overview of both the positive effects of MAO inhibition on AD as well as the potential risks associated with it. The article does not appear to contain any promotional content or partiality towards any particular viewpoint or opinion; rather it is objective in its presentation of facts and evidence. Furthermore, the article does not appear to contain any unsupported claims or missing points of consideration; rather it provides a comprehensive overview of the topic at hand with sufficient detail for readers to gain a thorough understanding of the subject matter.